替妥木单抗与安慰剂对比推荐方案静脉甲泼尼龙治疗中重度甲状腺眼病的眼球突出与复视反应:一项Meta分析与匹配调整间接比较
该匹配调整间接比较纳入12项静脉甲泼尼龙(IVMP)研究及替妥木单抗与安慰剂对照试验,比较眼球突出和复视反应。IVMP较安慰剂眼球突出差异为-0.16 mm(95%CI -1.55至1.22),无显著差异;替妥木单抗较IVMP眼球突出差异为-2.31 mm(95%CI -3.45至-1.17), favoring 替妥木单抗。IVMP较安慰剂复视反应无显著优势(OR 2.69,95%CI 0.94-7.70),替妥木单抗较IVMP有优势(OR 2.32,95%CI 1.07-5.03)。
要点
- IVMP较安慰剂眼球突出变化差异为-0.16 mm(95%CI -1.55至1.22),无显著差异。
- 替妥木单抗较IVMP眼球突出治疗差异为-2.31 mm(95%CI -3.45至-1.17), favor 替妥木单抗。
- 替妥木单抗较IVMP复视反应OR 2.32(95%CI 1.07-5.03),IVMP较安慰剂OR 2.69(95%CI 0.94-7.70)未达显著。
核心结论
- 本Meta分析提示IVMP较安慰剂眼球突出变化小、通常无临床意义,复视变化 modest。
- 该非随机比较提示替妥木单抗较IVMP眼球突出改善更大,复视降低1级或以上的可能性约为其两倍。
- 作者认为需开展随机试验比较两种治疗以确定是否一种在临床相关程度上优于另一种。
研究设计与样本
- 匹配调整间接比较,纳入替妥木单抗试验的患者个体数据与文献中IVMP最推荐方案的聚合数据。
- 检索PubMed和Embase,最终纳入12项IVMP研究(眼球突出变化11项 n=419;复视反应4项 n=125)及2项替妥木单抗(n=79)与安慰剂(n=83)对照研究。
主要发现
- IVMP较安慰剂基线至第12周眼球突出差异为-0.16 mm(95%CI -1.55至1.22 mm)。
- IVMP与替妥木单抗眼球突出治疗差异为-2.31 mm(95%CI -3.45至-1.17 mm), favor 替妥木单抗。
- IVMP较安慰剂复视反应OR 2.69(95%CI 0.94-7.70),未优于安慰剂。
- 替妥木单抗较IVMP复视反应OR 2.32(95%CI 1.07-5.03), favor 替妥木单抗。
局限性
- 本比较为非随机比较。
- 作者认为需开展随机试验比较替妥木单抗与IVMP以确定是否一种在临床相关程度上优于另一种。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Thyroid eye disease can be a debilitating autoimmune disorder characterized by progressive proptosis or diplopia. Teprotumumab has been compared with placebo in randomized clinical trials, but not with intravenous methylprednisolone (IVMP), which sometimes is used in clinical practice for this condition. OBJECTIVE: To conduct a matching-adjusted indirect comparison of teprotumumab vs IVMP vs placebo. DATA SOURCES: Deidentified patient-level data from teprotumumab trials and aggregate-level data from literature on the most recommended regimen of IVMP. STUDY SELECTION: PubMed and Embase were searched for randomized/observational studies using key terms and controlled vocabulary. Full texts of eligible articles were reviewed and cataloged. DATA EXTRACTION AND SYNTHESIS: Conducted by 1 reviewer (R.A.Q.) and 1 verifier (R.B.), including study characteristics, eligibility criteria, baseline characteristics, and outcomes. MAIN OUTCOMES AND MEASURES: Changes in proptosis by millimeter and diplopia response (percentage with ≥1 grade reduction) from baseline to week 12 in patients receiving IVMP and placebo, and to week 24 in patients receiving teprotumumab. RESULTS: The search identified 1019 records, and 6 through manual searches, alerts, and secondary references. After excluding duplicates and screening full-text records, 12 IVMP studies were included in the matching-adjusted indirect comparison (11 for proptosis change [n = 419], 4 for diplopia response [n = 125], and 2 teprotumumab [n = 79] and placebo [n = 83] comparator studies). Treatment with IVMP resulted in a proptosis difference of -0.16 mm (95% CI, -1.55 to 1.22 mm) from baseline to week 12 vs placebo. The proptosis treatment difference between IVMP and teprotumumab of -2.31 mm (95% CI, -3.45 to -1.17 mm) favored teprotumumab. Treatment with IVMP (odds ratio, 2.69; 95% CI, 0.94-7.70) was not favored over placebo in odds of diplopia response; however, teprotumumab was favored over IVMP (odds ratio, 2.32; 95% CI, 1.07-5.03). CONCLUSIONS AND RELEVANCE: This meta-analysis suggests that use of IVMP is associated with a small, typically not clinically relevant, change from baseline in proptosis vs placebo, with modest changes in diplopia. While this nonrandomized comparison suggests that use of teprotumumab, compared with IVMP, is associated with greater improvements in proptosis and may be twice as likely to have a 1 grade or higher reduction in diplopia, randomized trials comparing these 2 treatments would be warranted to determine if 1 treatment is superior to the other to a clinically relevant degree.
引用
- Douglas RS, Dailey R, Subramanian PS, et al. Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison. JAMA Ophthalmol. 2022. PMID: 35175308. doi:10.1001/jamaophthalmol.2021.6284
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。